{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:07:22Z","timestamp":1790838442277,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T00:00:00Z","timestamp":1570752000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T00:00:00Z","timestamp":1570752000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"crossref","award":["70112351"],"award-info":[{"award-number":["70112351"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Actinic keratoses (AK) are common precancerous lesions of the skin due to cumulative sun exposure. A variety of interventions are available for the treatment; however, the majority of randomised controlled trials (RCTs) and meta-analyses focus on short-term efficacy outcomes. This network meta-analysis aims to investigate the long-term (&gt;\u200912 months) efficacy of interventions for AK.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>To identify relevant studies, we will perform a systematic literature research in MEDLINE, Embase, and CENTRAL and hand-search pertinent trial registers. Two authors will independently screen titles and abstracts for eligibility. We will include RCTs with an inter-individual (parallel arm) design. The study population includes patients with a clinical or histopathologic diagnosis of AK. Eligibility will be restricted to the following interventions: surgical approaches, cryosurgery, ablative laser treatment, topical drug treatment with 5-fluorouracil, imiquimod, ingenol mebutate, diclofenac, or photodynamic therapy. As outcomes, we will consider the following endpoints: (1) the participant complete clearance rate, (2) the participant partial clearance rate, (3) the lesion-specific clearance, (4) the mean lesion reduction per patient, and (5) the number of withdrawals due to adverse events after at least 12 months after the end of treatment. Monotherapy or placebo will serve as a comparison. Estimates of effects from individual studies will be pooled using a random-effects model. Heterogeneity will be evaluated based on <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup> and chi-square test. The risk of bias will be estimated with the Cochrane Risk of Bias Tool by two review authors independently. The quality of evidence of the outcomes will be assessed with the GRADE approach. A network meta-analysis will be performed to combine direct and indirect evidence from the included RCTs.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>The potential of interventions to achieve a sustained clearance of AK has not been assessed to date. To investigate the long-term efficacy of interventions is important as the natural disease course is highly variable and relapses occur frequently even after initial lesion clearance. This review will help to set a framework for clinical decision making in patients with AK.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Systematic review registration<\/jats:title>\n                <jats:p>CRD42018095903 (PROSPERO)<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13643-019-1156-8","type":"journal-article","created":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T10:03:23Z","timestamp":1570788203000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Long-term efficacy of interventions for actinic keratosis: protocol for a systematic review and network meta-analysis"],"prefix":"10.1186","volume":"8","author":[{"given":"Theresa","family":"Steeb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus V.","family":"Heppt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Kohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars E.","family":"French","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0229-8931","authenticated-orcid":false,"given":"Carola","family":"Berking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,11]]},"reference":[{"issue":"1 Pt 2","key":"1156_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1067\/mjd.2000.103342","volume":"42","author":"SJ Salasche","year":"2000","unstructured":"Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol. 2000;42(1 Pt 2):4\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1156_CR2","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1067\/mjd.2000.103343","volume":"42","author":"Ronald L. Moy","year":"2000","unstructured":"Moy RL. Clinical presentation of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol. 2000;42(1 Pt 2):8-10.","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"11","key":"1156_CR3","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1002\/cncr.24284","volume":"115","author":"VD Criscione","year":"2009","unstructured":"Criscione VD, Weinstock MA, Naylor MF, Luque C, Eide MJ, Bingham SF, et al. Actinic keratoses: natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer. 2009;115(11):2523\u201330.","journal-title":"Cancer"},{"issue":"3","key":"1156_CR4","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/bjd.12420","volume":"169","author":"RN Werner","year":"2013","unstructured":"Werner RN, Sammain A, Erdmann R, Hartmann V, Stockfleth E, Nast A. The natural history of actinic keratosis: a systematic review. Br J Dermatol. 2013;169(3):502\u201318.","journal-title":"Br J Dermatol"},{"issue":"8","key":"1156_CR5","doi-asserted-by":"publisher","first-page":"997","DOI":"10.2340\/00015555-2692","volume":"97","author":"R Cerio","year":"2017","unstructured":"Cerio R, Dirschka T, Dreno B, Figueras Nart I, Lear JT, Pellacani G, et al. Actinic Keratosis, a Chronic, Progressive disease: understanding clinical gaps to optimise patient management. Acta Derm Venereol. 2017;97(8):997\u20138.","journal-title":"Acta Derm Venereol"},{"issue":"11","key":"1156_CR6","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1111\/jdv.13180","volume":"29","author":"RN Werner","year":"2015","unstructured":"Werner RN, Stockfleth E, Connolly SM, Correia O, Erdmann R, Foley P, et al. Evidence- and consensus-based (S3) Guidelines for the treatment of actinic keratosis\u2014International League of Dermatological Societies in cooperation with the European Dermatology Forum\u2014Short version. J Eur Acad Dermatol Venereol. 2015;29(11):2069\u201379.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"1","key":"1156_CR7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/bjd.15107","volume":"176","author":"D de Berker","year":"2017","unstructured":"de Berker D, McGregor JM, Mohd Mustapa MF, Exton LS, Hughes BR. British Association of Dermatologists' guidelines for the care of patients with actinic keratosis 2017. Br J Dermatol. 2017;176(1):20\u201343.","journal-title":"Br J Dermatol."},{"key":"1156_CR8","doi-asserted-by":"crossref","unstructured":"Heppt MV, Steeb T, Niesert AC, Zacher M, Leiter U, Garbe C, et al. Local interventions for actinic keratosis in organ transplant recipients: a systematic review. Br J Dermatol. 2018.","DOI":"10.1111\/bjd.17148"},{"key":"1156_CR9","doi-asserted-by":"crossref","unstructured":"Steeb T, Schlager JG, Kohl C, Ruzicka T, Heppt MV, Berking C. Laser-assisted photodynamic therapy for actinic keratosis: a systematic review and meta-analysis. J Am Acad Dermatol. 2018.","DOI":"10.1016\/j.jaad.2018.09.021"},{"issue":"5","key":"1156_CR10","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/j.1365-4632.2009.04045.x","volume":"48","author":"DA Askew","year":"2009","unstructured":"Askew DA, Mickan SM, Soyer HP, Wilkinson D. Effectiveness of 5-fluorouracil treatment for actinic keratosis\u2014a systematic review of randomized controlled trials. Int J Dermatol. 2009;48(5):453\u201363.","journal-title":"Int J Dermatol."},{"issue":"2","key":"1156_CR11","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/bjd.12343","volume":"169","author":"AK Gupta","year":"2013","unstructured":"Gupta AK, Paquet M. Network meta-analysis of the outcome 'participant complete clearance' in nonimmunosuppressed participants of eight interventions for actinic keratosis: a follow-up on a Cochrane review. Br J Dermatol. 2013;169(2):250\u20139.","journal-title":"Br J Dermatol."},{"issue":"9","key":"1156_CR12","doi-asserted-by":"publisher","first-page":"939","DOI":"10.2217\/imt.12.93","volume":"4","author":"M Rahvar","year":"2012","unstructured":"Rahvar M, Lamel SA, Maibach HI. Randomized, vehicle-controlled trials of topical 5-fluorouracil therapy for actinic keratosis treatment: an overview. Immunotherapy. 2012;4(9):939\u201345.","journal-title":"Immunotherapy."},{"issue":"3","key":"1156_CR13","first-page":"e123","volume":"3","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Open Med. 2009;3(3):e123\u201330.","journal-title":"Open Med."},{"key":"1156_CR14","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13643-016-0191-y","volume":"5","author":"D Moher","year":"2016","unstructured":"Moher D, Stewart L, Shekelle P. Implementing PRISMA-P: recommendations for prospective authors. Syst Rev. 2016;5:15.","journal-title":"Syst Rev."},{"key":"1156_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.","journal-title":"Syst Rev."},{"issue":"11","key":"1156_CR16","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777\u201384.","journal-title":"Ann Intern Med."},{"key":"1156_CR17","doi-asserted-by":"crossref","unstructured":"Efthimiou O, Mavridis D, Nikolakopoulou A, Rucker G, Trelle S, Egger M, et al. A model for meta-analysis of correlated binary outcomes: the case of split-body interventions. Stat Methods Med Res. 2017:962280217746436.","DOI":"10.1177\/0962280217746436"},{"key":"1156_CR18","volume":"12","author":"AK Gupta","year":"2012","unstructured":"Gupta AK, Paquet M, Villanueva E, Brintnell W. Interventions for actinic keratoses. The Cochrane database of systematic reviews. 2012;12:Cd004415.","journal-title":"The Cochrane database of systematic reviews."},{"key":"1156_CR19","unstructured":"R Core Team. A language and environment for statistical computing. R Foundation for Statistical Computing. Vienna, Austria; 2013."},{"key":"1156_CR20","unstructured":"Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre TCC, 2014."},{"key":"1156_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/9780470712184","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series: The Cochrane Collaboration","author":"JPT Higgins","year":"2008","unstructured":"Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series: The Cochrane Collaboration; 2008."},{"issue":"1","key":"1156_CR22","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/sim.2514","volume":"26","author":"W Viechtbauer","year":"2007","unstructured":"Viechtbauer W. Confidence intervals for the amount of heterogeneity in meta-analysis. Stat Med. 2007;26(1):37\u201352.","journal-title":"Stat Med."},{"issue":"4","key":"1156_CR23","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1002\/jrsm.1058","volume":"3","author":"G Rucker","year":"2012","unstructured":"Rucker G. Network meta-analysis, electrical networks and graph theory. Res Synth Methods. 2012;3(4):312\u201324.","journal-title":"Res Synth Methods."},{"issue":"25","key":"1156_CR24","doi-asserted-by":"publisher","first-page":"4353","DOI":"10.1002\/sim.6236","volume":"33","author":"G Rucker","year":"2014","unstructured":"Rucker G, Schwarzer G. Reduce dimension or reduce weights? Comparing two approaches to multi-arm studies in network meta-analysis. Stat Med. 2014;33(25):4353\u201369.","journal-title":"Stat Med."},{"issue":"1","key":"1156_CR25","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1002\/jrsm.1143","volume":"7","author":"G Rucker","year":"2016","unstructured":"Rucker G, Schwarzer G. Automated drawing of network plots in network meta-analysis. Res Synth Methods. 2016;7(1):94\u2013107.","journal-title":"Res Synth Methods."},{"key":"1156_CR26","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","volume":"15","author":"G Rucker","year":"2015","unstructured":"Rucker G, Schwarzer G. Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med Res Methodol. 2015;15:58.","journal-title":"BMC Med Res Methodol."},{"issue":"2","key":"1156_CR27","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/jrsm.1037","volume":"3","author":"G Salanti","year":"2012","unstructured":"Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods. 2012;3(2):80\u201397.","journal-title":"Res Synth Methods."},{"issue":"20","key":"1156_CR28","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1002\/sim.1875","volume":"23","author":"G Lu","year":"2004","unstructured":"Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004;23(20):3105\u201324.","journal-title":"Stat Med."},{"issue":"7521","key":"1156_CR29","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1136\/bmj.331.7521.897","volume":"331","author":"DM Caldwell","year":"2005","unstructured":"Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ. 2005;331(7521):897\u2013900.","journal-title":"BMJ."},{"issue":"7387","key":"1156_CR30","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1136\/bmj.326.7387.472","volume":"326","author":"F Song","year":"2003","unstructured":"Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ. 2003;326(7387):472.","journal-title":"BMJ."},{"issue":"1","key":"1156_CR31","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1093\/ije\/dys222","volume":"42","author":"AA Veroniki","year":"2013","unstructured":"Veroniki AA, Vasiliadis HS, Higgins JP, Salanti G. Evaluation of inconsistency in networks of interventions. Int J Epidemiol. 2013;42(1):332\u201345.","journal-title":"Int J Epidemiol."},{"issue":"7-8","key":"1156_CR32","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/sim.3767","volume":"29","author":"S Dias","year":"2010","unstructured":"Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Stat Med. 2010;29(7-8):932\u201344.","journal-title":"Stat Med."},{"issue":"2","key":"1156_CR33","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/jrsm.1045","volume":"3","author":"IR White","year":"2012","unstructured":"White IR, Barrett JK, Jackson D, Higgins JP. Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. Res Synth Methods. 2012;3(2):111\u201325.","journal-title":"Res Synth Methods."},{"key":"1156_CR34","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jclinepi.2017.10.005","volume":"93","author":"R Brignardello-Petersen","year":"2018","unstructured":"Brignardello-Petersen R, Bonner A, Alexander PE, Siemieniuk RA, Furukawa TA, Rochwerg B, et al. Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis. J Clin Epidemiol. 2018;93:36\u201344.","journal-title":"J Clin Epidemiol."},{"key":"1156_CR35","doi-asserted-by":"publisher","first-page":"g5630","DOI":"10.1136\/bmj.g5630","volume":"349","author":"MA Puhan","year":"2014","unstructured":"Puhan MA, Schunemann HJ, Murad MH, Li T, Brignardello-Petersen R, Singh JA, et al. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ. 2014;349:g5630.","journal-title":"BMJ."},{"key":"1156_CR36","doi-asserted-by":"crossref","unstructured":"Brignardello-Petersen R, Mustafa RA, Siemieniuk RAC, Murad MH, Agoritsas T, Izcovich A, et al. GRADE approach to rate the certainty from a network meta-analysis: Addressing Incoherence. J Clin Epidemiol. 2018.","DOI":"10.1016\/j.jclinepi.2018.11.025"},{"issue":"3","key":"1156_CR37","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.clindermatol.2017.08.013","volume":"36","author":"C Conforti","year":"2018","unstructured":"Conforti C, Beninanti E, Dianzani C. Are actinic keratoses really squamous cell cancer? How do we know if they would become malignant? Clin Dermatol. 2018;36(3):430\u20132.","journal-title":"Clin Dermatol."},{"issue":"6","key":"1156_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0096829","volume":"9","author":"S Vegter","year":"2014","unstructured":"Vegter S, Tolley K. A network meta-analysis of the relative efficacy of treatments for actinic keratosis of the face or scalp in Europe. PLoS One. 2014;9(6):e96829.","journal-title":"PLoS One."}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-019-1156-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13643-019-1156-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-019-1156-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T23:04:39Z","timestamp":1602284679000},"score":1,"resource":{"primary":{"URL":"https:\/\/systematicreviewsjournal.biomedcentral.com\/articles\/10.1186\/s13643-019-1156-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,11]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1156"],"URL":"https:\/\/doi.org\/10.1186\/s13643-019-1156-8","relation":{},"ISSN":["2046-4053"],"issn-type":[{"value":"2046-4053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,11]]},"assertion":[{"value":"8 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CB has been a member of advisory boards for Almirall Hermal, Biofrontera, Galderma, ISDIN, and Leo Pharma. CB has received speaker\u00b4s honoraria by Almirall Hermal, Galderma, and Leo Pharma. CB has received funding for clinical research by Leo Pharma. The remaining authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"237"}}